BRIVARACETAM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BRIVARACETAM (BRIVARACETAM).
Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand, binding to SV2A with 15- to 30-fold higher affinity than levetiracetam. It modulates neurotransmitter release, reducing neuronal excitability. It also inhibits voltage-gated sodium channels at clinically relevant concentrations.
| Metabolism | Brivaracetam is primarily metabolized by hydrolysis of the acetamide group via amide bond hydrolysis (not cytochrome P450), forming the inactive carboxylic acid metabolite (M1). A minor pathway is hydroxylation via CYP2C19, producing the hydroxyl metabolite (M2). |
| Excretion | Approximately 95% of the dose is excreted renally, with about 8-12% as unchanged drug and the remainder as metabolites (primarily by hydrolysis to the carboxylic acid metabolite). Fecal excretion accounts for less than 1%. |
| Half-life | Terminal elimination half-life is approximately 9 hours in adults with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to about 20-30 hours, requiring dose adjustment. |
| Protein binding | Less than 20% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). Binding is concentration-independent and low, minimizing displacement interactions. |
| Volume of Distribution | Volume of distribution is approximately 0.5 L/kg (range 0.3-0.6 L/kg), indicating distribution into total body water with moderate tissue binding. |
| Bioavailability | Oral bioavailability is approximately 90% (range 80-100%), with rapid absorption. Food does not significantly affect absorption. Absolute bioavailability is 100% for intravenous administration. |
| Onset of Action | For intravenous administration, clinical effect (e.g., seizure cessation) may be observed within 5-10 minutes following infusion. Oral tablets achieve peak plasma concentrations in approximately 1 hour, with onset of action expected within 1-2 hours. |
| Duration of Action | Duration of antiseizure effect is approximately 12 hours, consistent with twice-daily dosing. Steady-state is achieved within 2 days of repeated dosing. |
50 mg orally twice daily, with or without food. May increase to 100 mg twice daily based on tolerability and efficacy. Maximum 200 mg twice daily.
| Dosage form | TABLET |
| Renal impairment | CrCl ≥50 mL/min: no adjustment. CrCl 30-49 mL/min: 25-50 mg twice daily. CrCl 15-29 mL/min: 12.5-25 mg twice daily. CrCl <15 mL/min: 12.5-25 mg once daily. Hemodialysis: 12.5-25 mg once daily, with supplemental dose after dialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 12.5-25 mg twice daily, initial dose 12.5 mg twice daily. Child-Pugh C: not recommended. |
| Pediatric use | Age ≥1 month to <16 years: weight-based dosing. Initially 1.25 mg/kg twice daily, maximum 2.5 mg/kg twice daily. Total daily dose range: 2.5-5 mg/kg/day. Maximum 200 mg/day. |
| Geriatric use | Initiate at lower dose (12.5-25 mg twice daily) due to decreased renal function; titrate slowly. Monitor renal function and neuropsychiatric effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BRIVARACETAM (BRIVARACETAM).
| Breastfeeding | Brivaracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Infant exposure estimated at 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation, poor feeding, and weight gain. Benefit of breastfeeding may outweigh risks with caution. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show increased fetal malformations (e.g., skeletal abnormalities) at clinically relevant doses. Second and third trimesters: Potential for neurodevelopmental effects; avoid use unless benefit outweighs risk. Overall: Considered possibly teratogenic (FDA Pregnancy Category C equivalent). |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to brivaracetam or any of its inactive ingredients"]
| Precautions | ["Suicidal ideation and behavior: Monitor for emergence or worsening of depression, suicidal thoughts/behavior, or unusual mood changes.","Neurological adverse reactions: Dizziness, somnolence, and coordination difficulties (ataxia, gait disturbance, vertigo).","Withdrawal: Abrupt discontinuation may precipitate withdrawal seizures; taper gradually."] |
| Food/Dietary | No significant food interactions. Alcohol may increase central nervous system depression; avoid or limit alcohol consumption. |
Loading safety data…
| Fetal Monitoring | Maternal: Monitor seizure frequency, renal function, and serum drug levels (if available). Fetal: Ultrasound for structural anomalies (20 weeks), growth scans (third trimester), and neonatal assessment for withdrawal or adverse effects (sedation, irritability). |
| Fertility Effects | No specific human studies on fertility. Animal studies show no significant effects on male or female fertility at therapeutic doses. Overall, unlikely to impair fertility, but consider underlying epilepsy etiology. |
| Clinical Pearls |
| Brivaracetam is a SV2A ligand with higher affinity and selectivity than levetiracetam. It does not require dose adjustment in renal impairment unless creatinine clearance <30 mL/min. Do not use in patients with hepatic impairment. Onset of action is rapid; oral and IV formulations are bioequivalent. Monitor for psychiatric symptoms (e.g., aggression, psychosis) and somnolence. No need for titration; starting dose 50-100 mg/day divided twice daily. |
| Patient Advice | Take brivaracetam exactly as prescribed, with or without food. · Do not stop taking this medication suddenly, as it may increase seizure frequency. · Report any mood changes, aggression, or thoughts of self-harm immediately. · May cause drowsiness or dizziness; avoid driving until you know how it affects you. · If you have liver disease, inform your doctor before starting brivaracetam. · Store at room temperature, away from moisture and heat. |